These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22873540)

  • 1. Preclinical success against Alzheimer's disease with an old drug.
    LaFerla FM
    N Engl J Med; 2012 Aug; 367(6):570-2. PubMed ID: 22873540
    [No Abstract]   [Full Text] [Related]  

  • 2. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
    Cramer PE; Cirrito JR; Wesson DW; Lee CY; Karlo JC; Zinn AE; Casali BT; Restivo JL; Goebel WD; James MJ; Brunden KR; Wilson DA; Landreth GE
    Science; 2012 Mar; 335(6075):1503-6. PubMed ID: 22323736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicine. Old drug, new hope for Alzheimer's disease.
    Strittmatter WJ
    Science; 2012 Mar; 335(6075):1447-8. PubMed ID: 22442467
    [No Abstract]   [Full Text] [Related]  

  • 4. Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.
    Bonet-Costa V; Herranz-Pérez V; Blanco-Gandía M; Mas-Bargues C; Inglés M; Garcia-Tarraga P; Rodriguez-Arias M; Miñarro J; Borras C; Garcia-Verdugo JM; Viña J
    J Alzheimers Dis; 2016; 51(3):701-11. PubMed ID: 26890773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Veeraraghavalu K; Zhang C; Miller S; Hefendehl JK; Rajapaksha TW; Ulrich J; Jucker M; Holtzman DM; Tanzi RE; Vassar R; Sisodia SS
    Science; 2013 May; 340(6135):924-f. PubMed ID: 23704555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Price AR; Xu G; Siemienski ZB; Smithson LA; Borchelt DR; Golde TE; Felsenstein KM
    Science; 2013 May; 340(6135):924-d. PubMed ID: 23704553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Tesseur I; Lo AC; Roberfroid A; Dietvorst S; Van Broeck B; Borgers M; Gijsen H; Moechars D; Mercken M; Kemp J; D'Hooge R; De Strooper B
    Science; 2013 May; 340(6135):924-e. PubMed ID: 23704554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
    Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
    Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
    Saxena U
    Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease.
    Shin J
    Int J Geriatr Psychiatry; 2011 May; 26(5):546-8. PubMed ID: 21446001
    [No Abstract]   [Full Text] [Related]  

  • 11. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
    Cummings JL; Zhong K; Kinney JW; Heaney C; Moll-Tudla J; Joshi A; Pontecorvo M; Devous M; Tang A; Bena J
    Alzheimers Res Ther; 2016 Jan; 8():4. PubMed ID: 26822146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alzheimer disease: the temptation coming from off-label use].
    Nau JY
    Rev Med Suisse; 2012 Feb; 8(330):482-3. PubMed ID: 22452136
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Landreth GE; Cramer PE; Lakner MM; Cirrito JR; Wesson DW; Brunden KR; Wilson DA
    Science; 2013 May; 340(6135):924-g. PubMed ID: 23704556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Fitz NF; Cronican AA; Lefterov I; Koldamova R
    Science; 2013 May; 340(6135):924-c. PubMed ID: 23704552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels.
    Timmer NM; van Dijk L; van der Zee CE; Kiliaan A; de Waal RM; Verbeek MM
    Neurobiol Dis; 2010 Oct; 40(1):340-7. PubMed ID: 20600909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.
    Balducci C; Paladini A; Micotti E; Tolomeo D; La Vitola P; Grigoli E; Richardson JC; Forloni G
    J Alzheimers Dis; 2015; 46(2):471-82. PubMed ID: 25777514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latest Alzheimer's research: some rays of hope.
    Johns Hopkins Med Lett Health After 50; 2012 May; 24(3):1-2. PubMed ID: 22649822
    [No Abstract]   [Full Text] [Related]  

  • 18. Alzheimer's disease 2012: the great amyloid gamble.
    Marchesi VT
    Am J Pathol; 2012 May; 180(5):1762-7. PubMed ID: 22472273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alzheimer's disease--the molecular biological mechanism and the therapeutic drug design].
    Nabeshima T; Takeda M
    Nihon Yakurigaku Zasshi; 1996 Sep; 108(3):132-4. PubMed ID: 9091440
    [No Abstract]   [Full Text] [Related]  

  • 20. Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study.
    Mirza Z; Beg MA
    Curr Alzheimer Res; 2017; 14(3):327-334. PubMed ID: 27842487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.